Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant PE versus FEC chemotherapy for stage IIb/III breast cancer
ChiCTR-TRC-10001043Phase 4Completed
- Sponsor
- West China Hospital of Sichuan University
- Start
- Sep 2009
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of paclitaxel, epirubicin, fluorouracil and cyclophosphamide in breast cancer (2 arms), sponsored by West China Hospital of Sichuan University. Primary endpoints: Breast conservation therapy rate and Pathologic complete response. Started Sep 2009; status: completed.
02
Drugs
paclitaxelepirubicinfluorouracilcyclophosphamide
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR-TRC-10001043.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-TRC-10001043.